Screener
Hemab Therapeutics Holdings, Inc. COAG EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss before income tax expense | (24,053) | (12,205) | (46,728) | (27,701) |
| Income tax (expense) benefit | (97) | (4) | (109) | 186 |
| Net loss | $(24,150) | $(12,209) | $(46,837) | $(27,515) |
| Net loss per share, basic and diluted | $(0.80) | $(12.91) | $(3.00) | $(29.09) |
| Weighted average shares outstanding, basic and diluted | 30,111,338 | 946,000 | 15,609,236 | 946,000 |
| Other comprehensive loss | ||||
| Net loss | $(24,150) | $(12,209) | $(46,837) | $(27,515) |
| Net unrealized (loss) gain on available-for-sale debt securities | (2,309) | (609) | (2,923) | 365 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s EPS (diluted)?
- Hemab Therapeutics Holdings, Inc. (COAG) reported EPS (diluted) of -$0.80 in Q2 2026.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude